Pfizer Japan recalls high blood pressure drug over cancer-causing impurity
TOKYO (Reuters) - The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday.
More than 763,000 tablets of the drug Amvalo, manufactured from April to July in Mylan Laboratories Limited in India, are the subject of recall, Pfizer Japan Inc said in a statement, adding there were no reports of any damage to health.
“We will fully pay careful attention to our manufacturing and quality control to prevent a recurrence,” Pfizer Japan President Akihisa Harada said.
Mylan NV said in November it would recall certain batches of blood pressure medicine valsartan in the United States after they were found to contain a probable cancer-causing impurity.
Chinese pharmaceutical ingredient manufacturer Zhejiang Huahai Pharmaceuticals also said in July it would recall valsartan from consumers in the United States after finding traces of a probable carcinogen.
Last year, the Japanese Health Ministry asked pharmaceutical firms to check whether any of their drugs using valsartan contained any carcinogenic impurities.
https://www.reuters.com/article/us-pfizer-japan-recall/pfizer-japan-recalls-high-blood-pressure-drug-over-cancer-causing-impurity-idUSKCN1PX19R?utm_campaign=trueAnthem:+Trending+Content&utm_content=5c5e496204d3017221aa70b6&utm_medium=trueAnthem&utm_source=twitter